The latest price target for NewAmsterdam Pharma (NASDAQ:NAMS) was reported by RBC Capital on January 24, 2025. The analyst firm set a price target for $40.00 expecting NAMS to rise to within 12 months (a possible 69.49% upside). 17 analyst firms have reported ratings in the last year.

The latest analyst rating for NewAmsterdam Pharma (NASDAQ:NAMS) was provided by RBC Capital, and NewAmsterdam Pharma reiterated their outperform rating.

There is no last upgrade for NewAmsterdam Pharma

There is no last downgrade for NewAmsterdam Pharma.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of NewAmsterdam Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for NewAmsterdam Pharma was filed on January 24, 2025 so you should expect the next rating to be made available sometime around January 24, 2026.

While ratings are subjective and will change, the latest NewAmsterdam Pharma (NAMS) rating was a reiterated with a price target of $40.00 to $40.00. The current price NewAmsterdam Pharma (NAMS) is trading at is $23.60, which is out of the analyst’s predicted range.